X4 Pharmaceuticals: An Undercovered Biotech Trade With A Funded Path To FDA Approval
Source: SeekingAlpha
2026-03-03 10:04:28 ET
Summary
After years of volatility and a brutal post-COVID correction, biotech investors have understandably become more selective. In the current climate, investors are looking for companies with funded clinical trials, tangible product pipelines, and balance sheets that don’t require equal-parts dilution and wishful thinking....
Read the full article on Seeking Alpha
For further details see:
X4 Pharmaceuticals: An Undercovered Biotech Trade With A Funded Path To FDA Approval
BioCryst Pharmaceuticals Inc.
NASDAQ: BCRX
BCRX Trading
-1.71% G/L:
$8.325 Last:
1,409,572 Volume:
$8.40 Open:
BCRX Latest News
February 26, 2026 07:00:00 am
BioCryst Reports Full Year 2025 Financial Results and Provides Business Update
BCRX Stock Data
$1,391,931,498
199,991,369
0.01%
88
N/A
Biotechnology & Life Sciences
Healthcare
US
Durham
